HLA-DPB1 and chronic beryllium disease: A HuGE review

American Journal of Epidemiology

Volumn 157, Issue 5, 2003, Pages 388-398

  McCanlies, Erin C ^a   Kreiss, Kathleen ^a   Andrew, Michael ^a   Weston, Ainsley ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Berylliosis; Beryllium; Chronic beryllium disease; Epidemiology; Genetic screening; HLA DP antigens; HLA DPB1; Occupational exposure

Indexed keywords

BERYLLIUM; HLA DP ANTIGEN; HLA DPB1 ANTIGEN; UNCLASSIFIED DRUG;

BERYLLIUM; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT;

BERYLLIOSIS; CHROMOSOME 6; CHRONIC DISEASE; CHRONIC LUNG DISEASE; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; HLA SYSTEM; HUMAN; HUMAN GENOME; LUNG DISEASE; LUNG GRANULOMA; MAJOR CLINICAL STUDY; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL LUNG DISEASE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; RISK ASSESSMENT;

BERYLLIOSIS; CHROMOSOMES, HUMAN, PAIR 6; CHRONIC DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HLA-DP ANTIGENS; HUMANS; OCCUPATIONAL DISEASES; VARIATION (GENETICS);

EID: 0037369674     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwg001     Document Type: Review

References (79)

1. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921.
2. Benjamin E, Leskowitz S. Immunology: a short course. New York, NY: Wiley-Liss, Inc, 1991.
3. Apple RJ, Erlich H. HLA class II genes: structure and diversity. In: Browning MJ, McMichael AJ, eds. HLA and MHC: genes, molecules and function. Oxford, United Kingdom: BIOS Scientific Publishers Ltd, 1996.
4. Marsh SG. Nomenclature for factors of the HLA system, update March 1998. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens 1998;51:681-3.
5. Steiner LL, Wu J, Noreen HJ, et al. Four new DP alleles identified in a study of 500 unrelated bone marrow donor-recipient pairs. Tissue Antigens 1999;53:201-6.
6. Voorter CE, Tilanus MG, van den Berg-Loonen EM. Two new HLA DPB1 alleles identified by sequence-based typing: DPB1 *8201 and DPB1 *8301. Tissue Antigens 2000;56:560-2.
7. Marsh SG. Nomenclature for factors of the HLA system, update September 2000. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens 2000;56:565-6.
8. Rozemuller EH, Van der Zwan AW, Voorter CE, et al. DPB1 *8501, a novel DPB1 variant in the US Black population. Tissue Antigens 2000;56:282-4.
9. Lui A, Lin J, Chen W, et al. Sequence of complete exon 2 and partial intron 2 of HLA-DPB1 *8001. (GenBank accession no. AF336231). Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine, 2001. (World Wide Web URL: http://www.ncbi.nlm.nih.gov).
10. European Bioinformatics Institute, European Molecular Biology Laboratory. IMGT: ImMunoGeneTics Database. Cambridge, United Kingdom: European Bioinformatics Institute, 2002. (World Wide Web URL: http://www.ebi.ac.uk/imgt).
11. Foley P, Lympany P, Puscinska E, et al. HLA-DPB1 and TAP1 polymorphisms in sarcoidosis. Chest 1997;111(suppl):73S.
12. Steiner LL, McCurdy DK, Cavalli A, et al. Two new DPB1 alleles identified in a study of the genetics of susceptibility to pauciarticular juvenile rheumatoid arthritis. Tissue Antigens 1997;49:262-6.
13. Fukazawa T, Kikuchi S, Sasaki H, et al. Genomic HLA profiles of MS in Hokkaido, Japan: important role of DPB1 *0501 allele. J Neurol 2000;247:175-8.
14. Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPB1 *0501associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 1999;122:1689-96.
15. Nishimaki K, Kawamura T, Inada H, et al. HLA DPB1 *0201 gene confers disease susceptibility in Japanese with childhood onset type I diabetes, independent of HLA-DR and DQ genotypes. Diabetes Res Clin Pract 2000;47:49-55.
16. Rani R, Sood A, Lazaro AM, et al. Associations of MHC class II alleles with insulin-dependent diabetes mellitus (IDDM) in patients from North India. Hum Immunol 1999;60:524-31.
17. Potolicchio I, Mosconi G, Forni A, et al. Susceptibility to hard metal lung disease is strongly associated with the presence of glutamate 69 in HLA-DP beta chain. Eur J Immunol 1997;27:2741-3.
18. Potolicchio I, Festucci A, Hausler P, et al. HLA-DP molecules bind cobalt: a possible explanation for the genetic association with hard metal disease. Eur J Immunol 1999;29:2140-7.
19. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993;262:242-4.
20. Richeldi L, Kreiss K, Mroz M, et al. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med 1997;32:337-40.
21. Wang Z, White PS, Petrovic M, et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol 1999;163:1647-53.
22. Wang Z, Farris GM, Newman LS, et al. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology 2001;165:27-38.
23. Saltini C, Richeldi L, Losi M, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001;18:677-84.
24. Rossman MD, Stubbs J, Lee CW, et al. Human leukocyte antigen class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002;165:788-94.
25. Gao XJ, Sun YP, An JB, et al. DNA typing for HLA-DR and -DP alleles in a Chinese population using the polymerase chain reaction (PCR) and oligonucleotide probes. Tissue Antigens 1991;38:24-30.
26. Falco M, Sun Y, Fernandez-Vina MA, et al. HLA-DPB1 alleles in a population from south China. Immunogenetics 1993;37:251-6.
27. Lienert K, Krishnan R, Fowler C, et al. HLA DPB1 genotyping in Australian aborigines by amplified fragment length polymorphism analysis. Hum Immunol 1993;36:137-41.
28. Titus-Trachtenberg EA, Richards O, De Stefano GF, et al. Analysis of HLA class II haplotypes in the Cayapa Indians of Ecuador: a novel DRB1 allele reveals evidence for convergent evolution and balancing selection at position 86. Am J Hum Genet 1994;55:160-7.
29. Briceno I, Gomez A, Bernal JE, et al. HLA-DPB1 polymorphism in seven South American Indian tribes in Colombia. Eur J Immunogenet 1996;23:235-40.
30. Ploski R, Ronningen KS, Thorsby E. HLA class II profile of a Polish population: frequencies of DRB1, DQA1, DQB1, and DPB1 alleles and DRB1-DQA1-DQB1 haplotypes. Transplant Proc 1996;28:3431-2.
31. Trachtenberg EA, Keyeux G, Bernal JE, et al. Results of Expedicion Humana. I. Analysis of HLA class II (DRB1-DQA1DPB1) alleles and DR-DQ haplotypes in nine Amerindian populations from Colombia. Tissue Antigens 1996;48:174-81.
32. Trachtenberg EA, Keyeux G, Bernal JE, et al. Results of Expedicion Humana. II. Analysis of HLA class II alleles in three African American populations from Colombia using the PCR/ SSOP: identification of a novel DQB1*02 (*0203) allele. Tissue Antigens 1996;48:192-8.
33. Just JJ, King MC, Thomson G, et al. African-American HLA class II allele and haplotype diversity. Tissue Antigens 1997; 49:547-55.
34. Cechova E, Fazekasova H, Ferencik S, et al. HLA-DRB1, -DQB1 and -DPB1 polymorphism in the Slovak population. Tissue Antigens 1998;51:574-6.
35. May J, Mockenhaupt FP, Loliger CC, et al. HLA DPA1/DPB1 genotype and haplotype frequencies, and linkage disequilibria in Nigeria, Liberia, and Gabon. Tissue Antigens 1998;52:199-207.
36. Poulton KV, Kennedy LJ, Ross J, et al. A study of HLA-DPB1 phenotypes reveals DPB1 *6301 in a rural population from Cameroon. Eur J Immunogenet 1998;25:375-7.
37. Loudova M, Sramkova I, Cukrova V, et al. Frequencies of HLA-DRB1, -DQB1 and -DPB1 alleles in Czech population. Folia Biol (Praha) 1999;45:27-30.
38. Zimdahl H, Schiefenhovel W, Kayser M, et al. Towards understanding the origin and dispersal of Austronesians in the Solomon Sea: HLA class II polymorphism in eight distinct populations of Asia-Oceania. Eur J Immunogenet 1999;26:405-16.
39. Meyer KC. Beryllium and lung disease. Chest 1994;106:942-6.
40. Newman L. Beryllium. In: Sullivan JB, Krieger GR, eds. Hazardous materials toxicology: clinical principles of environmental health. Baltimore, MD: Williams and Wilkins, 1992:882-90.
41. Williams WJ. Beryllium disease. In: Parkes WR, ed. Occupational lung disorders. 3rd ed. Oxford, United Kingdom: Butterworth-Heinemann, 1994:571-92.
42. International Agency for Research on Cancer. Some metals and metallic compounds: beryllium and beryllium compounds. (IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 23). Lyon, France: International Agency for Research on Cancer, 1980.
43. International Agency for Research on Cancer. Beryllium, cadmium, mercury, and exposure in the glass manufacturing industry. (IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 58). Lyon, France: International Agency for Research on Cancer, 1993.
44. Cullen MR, Cherniack MG, Kominsky JR. Chronic beryllium disease in the United States. Semin Respir Med 1986;7:203-9.
45. National Institute for Occupational Safety and Health. Criteria for a recommended standard: occupational exposure to beryllium. Washington, DC: US Department of Health, Education and Welfare, 1972. (DHEW publication no. (NIOSH) 72-10268).
46. National Institute for Occupational Safety and Health. Occupational hazard survey. Cincinnati, OH: National Institute for Occupational Safety and Health, 1978. (DHEW publication no. (NIOSH) 78-114).
47. Bayliss DL, Lainhart WS, Crally LJ, et al. Mortality patterns in a group of former beryllium workers. In: Transactions of the 33rd Annual Meeting of the American Conference of Governmental Industrial Hygienists, Toronto, Canada, 1971. Toronto, Ontario, Canada: American Conference of Governmental Industrial Hygienists, 1971:94-107.
48. Bayliss DL, Lainhart WS. Mortality patterns in beryllium production workers. Presented at the 1972 conference of the American Industrial Hygiene Association. (OSHA exhibit no. 66, docket no. H-005). Fairfax, VA: American Industrial Hygiene Association, 1972.
49. Bayliss DL, Wagoner JK. Bronchogenic cancer and cardiorespiratory disease mortality among white males employed in a beryllium production facility. Presented at a National Institute for Occupational Safety and Health hearing on beryllium, Cincinnati, Ohio, 1977. (Exhibit 13.F.). Cincinnati, OH: Industrywide Studies Branch, National Institute for Occupational Safety and Health, 1977.
50. Infante PF, Wagoner JK, Sprince NL. Mortality patterns from lung cancer and nonneoplastic respiratory disease among white males in the beryllium case registry. Environ Res 1980;21:35-43.
51. Mancuso TF, el Attar AA. Epidemiological study of the beryllium industry: cohort methodology and mortality studies. J Occup Med 1969;11:422-34.
52. Mancuso TF. Relation of duration of employment and prior respiratory illness to respiratory cancer among beryllium workers. Environ Res 1970;3:251-75.
53. Mancuso TF. Mortality study of beryllium industry workers' occupational lung cancer. Environ Res 1980;21:48-55.
54. Wagoner JK, Infante PF, Bayliss DL. Beryllium: an etiologic agent in the induction of lung cancer, nonneoplastic respiratory disease, and heart disease among industrially exposed workers. Environ Res 1980;21:15-34.
55. Mancuso TF. Occupational lung cancer among beryllium workers. In: Lemen R, Dement J, eds. Dusts and disease: proceedings of the conference on occupational exposures to fibrous and particulate dust and their extension into the environment, Park Forest South, IL: Pathotox Publishers, Inc, 1979.
56. Steenland K, Ward E. Lung cancer incidence among patients with beryllium disease: a cohort mortality study. J Natl Cancer Inst 1991;83:1380-5.
57. Ward E, Okun A, Ruder A, et al. A mortality study of workers at seven beryllium processing plants. Am J Ind Med 1992;22: 885-904.
58. Sanderson WT, Ward EM, Steenland K, et al. Lung cancer case-control study of beryllium workers. Am J Ind Med 2001; 39:133-44.
59. US Environmental Protection Agency. Health assessment document for beryllium. Washington, DC: Office of Health and Environmental Assessment, Environmental Protection Agency, 1987. (Publication no. EPA/600/8-84/026F).
60. Newman LS, Lloyd J, Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ Health Perspect 1996;104S(suppl):937-43.
61. Curtis GH. The diagnosis of beryllium disease with special reference to the patch test. Arch Ind Health 1959;19:150-3.
62. Bargon J, Kronenberger H, Bergmann L, et al. Lymphocyte transformation test in a group of foundry workers exposed to beryllium and non-exposed controls. Eur J Respir Dis Suppl 1986;146:211-15.
63. Kreiss K, Newman LS, Mroz MM, et al. Screening blood test identifies subclinical beryllium disease. J Occup Med 1989;31:603-8.
64. Kreiss K, Wasserman S, Mroz MM, et al. Beryllium disease screening in the ceramics industry: blood lymphocyte test performance and exposure-disease relations. J Occup Med 1993; 35:267-74.
65. Kreiss K, Mroz MM, Zhen B, et al. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 1993;148:985-91.
66. 3. Am J Ind Med 1996;30:16-25.
67. Stange AW, Furman FJ, Hilmas DE. Rocky Flats beryllium health surveillance. Environ Health Perspect 1996; 104S(suppl):981-6.
68. Kreiss K, Mroz MM, Zhen B, et al. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med 1997;54:605-12.
69. Henneberger PK, Cumro D, Deubner DD, et al. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001;74:167-76.
70. Sprince N, Kazemi H. Beryllium disease. In: Rom W, ed. Environmental and occupational medicine. New York, NY: Little, Brown and Company, 1992:781-90.
71. Eisenbud M, Lisson J. Epidemiological aspects of berylliuminduced nonmalignant lung disease: a 30-year update. J Occup Med 1983;25:196-202.
72. Williams WJ. United Kingdom beryllium registry: mortality and autopsy study. Environ Health Perspect 1996;104S(suppl):949-51.
73. Hardy HL, Rabe EW, Lorch S. United States Beryllium Case Registry (1952-1966): review of its methods and utility. J Occup Med 1967;9:271-6.
74. Sprince NL, Kazemi H. U.S. Beryllium Case Registry through 1977. Environ Res 1980;21:44-7.
75. Tepper L, Hardy HL, Chamberlin RI. Toxicity of beryllium compounds. Amsterdam, The Netherlands: Elsevier Publishing Company, 1961.
76. Holtzman NA. Medical and ethical issues in genetic screening-an academic view. Environ Health Perspect 1996; 104(suppl 5):987-90.
77. Weston A, Ensey J, Kreiss K, et al. Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to preemployment testing for chronic beryllium disease. Am J Ind Med 2002;41:457-65.
78. Van Damme K, Casteleyn L, Heseltine E, et al. Individual susceptibility and prevention of occupational diseases: scientific and ethical issues. J Occup Environ Med 1995;37:91-9.
79. Khoury MJ, Newill CA, Chase GA. Epidemiologic evaluation of screening for risk factors: application to genetic screening. Am J Public Health 1985;75:1204-8.